Anika Therapeutics, Inc. (ANIK)
21.21
+0.37
(+1.78%)
USD |
NASDAQ |
Aug 28, 12:05
Anika Therapeutics Cash from Operations (Quarterly) : -0.684M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.684M |
| March 31, 2026 | -4.846M |
| December 31, 2025 | 4.637M |
| September 30, 2025 | 6.87M |
| June 30, 2025 | -0.189M |
| March 31, 2025 | -0.13M |
| December 31, 2024 | 1.582M |
| September 30, 2024 | 5.016M |
| June 30, 2024 | -1.069M |
| March 31, 2024 | -0.126M |
| December 31, 2023 | 3.638M |
| September 30, 2023 | 6.485M |
| June 30, 2023 | -8.293M |
| March 31, 2023 | -3.618M |
| December 31, 2022 | 0.481M |
| September 30, 2022 | 2.709M |
| June 30, 2022 | 3.088M |
| March 31, 2022 | -1.869M |
| December 31, 2021 | 4.472M |
| September 30, 2021 | 2.062M |
| June 30, 2021 | 4.294M |
| March 31, 2021 | -2.431M |
| December 31, 2020 | 2.587M |
| September 30, 2020 | 5.865M |
| June 30, 2020 | 3.568M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.045M |
| December 31, 2019 | 13.02M |
| September 30, 2019 | 10.05M |
| June 30, 2019 | 5.47M |
| March 31, 2019 | 8.462M |
| December 31, 2018 | 10.01M |
| September 30, 2018 | 10.84M |
| June 30, 2018 | 4.471M |
| March 31, 2018 | 9.592M |
| December 31, 2017 | 6.979M |
| September 30, 2017 | 12.10M |
| June 30, 2017 | 6.271M |
| March 31, 2017 | 15.46M |
| December 31, 2016 | 5.844M |
| September 30, 2016 | 11.31M |
| June 30, 2016 | -1.037M |
| March 31, 2016 | 7.68M |
| December 31, 2015 | 15.27M |
| September 30, 2015 | 8.906M |
| June 30, 2015 | 10.90M |
| March 31, 2015 | 3.984M |
| December 31, 2014 | 14.76M |
| September 30, 2014 | 4.903M |
| June 30, 2014 | 6.722M |
| March 31, 2014 | 13.60M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -20.65M |
| MiMedx Group, Inc. | -10.03M |
| ABVC BioPharma, Inc. | -0.2444M |
| Enovis Corp. | 75.03M |
| Edwards Lifesciences Corp. | 651.90M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.28M |
| Cash from Financing (Quarterly) | -0.701M |
| Free Cash Flow | 0.562M |
| Free Cash Flow Per Share (Quarterly) | -0.1555 |
| Free Cash Flow to Equity (Quarterly) | -1.647M |
| Free Cash Flow to Firm (Quarterly) | -2.133M |
| Free Cash Flow Yield | 0.19% |